Details

Autor(en) / Beteiligte

• Spentzou, Aggeliki
• Bergin, Philip
• Gill, Dilbinder
• Cheeseman, Hannah
• Ashraf, Ambreen
• Kaltsidis, Harry
• Cashin-Cox, Michelle
• Anjarwalla, Insiyah
• Steel, Alan
• Higgs, Christopher
• Pozniak, Anton
• Piechocka-Trocha, Alicja
• Wong, Johnson
• Anzala, Omu
• Karita, Etienne
• Dally, Len
• Gotch, Frances
• Walker, Bruce
• Gilmour, Jill
• Hayes, Peter

Titel

Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV-1 Vaccine Candidates

Ist Teil von

• The Journal of infectious diseases, 2010-03, Vol.201 (5), p.720-729

Ort / Verlag

Oxford: The University of Chicago Press

Erscheinungsjahr

2010

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• We have characterized an assay measuring CD8 T cell-mediated inhibition of human immunodeficiency virus (HIV) type 1 replication, demonstrating specificity and reproducibility and employing a panel of primary HIV-1 isolates. The assay uses relatively simple autologous cell culture and enzyme-linked immunosorbent assay, avoids generation of T cell clones, and can be performed with <2 million peripheral blood mononuclear cells. Efficient CD8 T cell-mediated cross-clade inhibition of HIV-1 replication in vitro was demonstrated in antiretroviral therapy-naive HIV-1-infected subjects with controlled viral replication in vivo but not in viremic subjects. An HIV-1 vaccine candidate, consisting of DNA and recombinant adenovirus 5 vectors tested in a phase I clinical trial, induced CD8 T cells that efficiently inhibited HIV-1 in a HLA-I-dependent manner. Assessment of direct antiviral T cell function by this assay provides additional information to guide vaccine design and the prioritizing of candidates for further clinical trials.